GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » 3-Year Revenue Growth Rate

TRDA (Entrada Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics 3-Year Revenue Growth Rate?

Entrada Therapeutics's Revenue per Share for the three months ended in Dec. 2024 was $0.86.

During the past 12 months, Entrada Therapeutics's average Revenue per Share Growth Rate was 38.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Entrada Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Entrada Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's 3-Year Revenue Growth Rate falls into.


;
;

Entrada Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Entrada Therapeutics  (NAS:TRDA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Entrada Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
DNA RAPP UPB TECX HRTX ABSI BNTC RNAC ZBIO MRVI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Website
https://www.entradatx.com
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Executives
Kory James Wentworth officer: Chief Financial Officer 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Natarajan Sethuraman officer: Chief Scientific Officer 6 TIDE STREET, BOSTON MA 02210
Nathan J Dowden officer: Chief Operating Officer 6 TIDE STREET, BOSTON MA 02210
Dipal Doshi director, officer: President and CEO C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Peter S Kim director ONE MERCK DRIVE, P.O. BOX 100, WHITEHOUSE STATION X1 08889
Nerissa Kreher officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman director C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Bernhardt G Zeiher director ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
John F Crowley director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512